In this study, we reported the incidence of HRAS mutations among a large cohort of NSCLC patients, and we focused on the clinical-pathological features of four cases with HRAS p.Gln61Leu mutations. The gene discussed is HRAS; the disease is non-small cell lung carcinoma.